Results 61 to 70 of about 33,429 (298)

In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes

Pharmaceutics, 2020
DWP16001 is currently in a phase 2 clinical trial as a novel anti-diabetes drug for the treatment of type 2 diabetes by selective inhibition of sodium-glucose cotransporter 2.
Ju-Hyun Kim, Dong Kyun Kim, Won-Gu Choi, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song, Sangkyu Lee, Hye Suk Lee   +7 more
doaj   +1 more source

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure

Clinical Pharmacology &Therapeutics, EarlyView.
This study investigated genetic determinants of the pharmacokinetics of the CYP2C8 index drugs repaglinide and gemfibrozil, and their interaction in healthy participants. Sequencing data from a study with montelukast revealed a novel functional CYP2C8 allele (rs2071426, CYP2C8*19), predicted to create an intronic splice donor site.
Anssi J. H. Mykkänen, Päivi Hirvensalo, Kathrin Klein, Dorota Kaminska, Markus Grube, Tuija Tapaninen, Johanna I. Kiiski, Mikko Neuvonen, Ville T. Männistö, Jussi Pihlajamäki, Mladen Tzvetkov, Matthias Schwab, Aleksi Tornio, Janne T. Backman, Mikko Niemi   +14 more
wiley   +1 more source

Direct Quantification of Cannabinoids and Cannabinoid Glucuronides in Whole Blood by Liquid Chromatography Tandem Mass Spectrometry

Analytical and Bioanalytical Chemistry, 2011
The first method for quantifying cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry (LC–MS/MS) was developed and validated.
David M. Schwope, K. Scheidweiler, M. Huestis   +2 more
semanticscholar   +1 more source

Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions

Clinical Pharmacology &Therapeutics, EarlyView.
The intestinal microbiome is a key regulator of immune homeostasis, metabolism, and epithelial barrier integrity. In patients with malignant hematological diseases, particularly those undergoing hematopoietic stem cell transplantation, microbiome perturbations by reduced diversity, pathobiont expansion, and loss of beneficial metabolites are common as ...
Bálint Gergely Szabó, Dorina Korózs, Michal Bator, Krisztina Jeszenszky, Viktor Lakatos, László Gopcsa, Péter Reményi, János Sinkó   +7 more
wiley   +1 more source

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

Clinical Pharmacology &Therapeutics, EarlyView.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer, Raeanne M. Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B. Tiley, John K. Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L. R. Brouwer   +9 more
wiley   +1 more source

Synthesis of urolithin A 3- and 8-glucuronides via intramolecular biaryl coupling

Results in Chemistry
Urolithins, 6H-dibenzo[b,d]pyran-6-one derivatives, are metabolites produced by gut microbiota from ellagic acid, a natural antioxidant. They are more efficiently absorbed than ellagic acid and contribute to the health benefits of ellagitannin-rich foods.
Takanori Nagai, Shaikh Shoeb, Tsuyoshi Nishimori, Hiroyuki Tachi, Anees Pangal, Hitoshi Abe   +5 more
doaj   +1 more source

Antioxidative Flavonol Glucuronides and Anti-HBsAg Flavonol from Rotala rotundifolia

Journal of Traditional and Complementary Medicine, 2011
Two new flavonol glucuronides, quercetin 3-O-β-d-2″-acetylglucuronide (1) and quercetin 3-O-β-d-2″-acetylglucuronide methyl ester (2), along with four known flavonoids (3-6) were isolated from the whole parts of Rotala rotundifolia.
Li-Jie Zhang, Sheau-Farn Yeh, Ya-Ten Yu, Li-Ming Yang Kuo, Yao-Haur Kuo, Dr.   +4 more
doaj   +1 more source

Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine

Drug Testing and Analysis, EarlyView.
This study investigated tesofensine metabolism and urinary elimination after a single 483 μg intake via a dietary supplement. In six volunteers, urine was collected up to 659 h. LC‐HRMS/MS identified four tentative metabolites; maximum urinary concentrations reached 4 ng/mL within 4–48 h.
O. Krug, A. Thomas, M. Thevis
wiley   +1 more source

Hours Since Last Drink Is Associated With Multiple Urine Ethyl Glucuronide Cutoffs Among Individuals With Alcohol Use Disorder

Drug Testing and Analysis, EarlyView.
Higher uEtG results indicated more recent drinking, rather than higher levels of alcohol consumption, and the period of detection of uEtG was shorter than previously reported. Even at low cutoffs, uEtG was best conceptualized as a measure of alcohol consumption in the prior 24 h.
Julianne D. Jett, Mohammad Keshtkar, Emma Seidler, Katharine Palmer, Diana Tyutyunnyk, Rachael Beck, Sara C. Parent, Douglas L. Weeks, Naomi Chaytor, Sterling M. McPherson, Michael G. McDonell   +10 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source